News - Biotechnology, Amgen

Filter

Current filters:

BiotechnologyAmgen

Popular Filters

1 to 25 of 115 results

Sandoz application for biosimilar Neupogen accepted by US FDA

25-07-2014

The US Food and Drug Administration has accepted the Biologics License Application for filgrastim, which…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyRegulationSandozUSAZarzio

Amgen’s evolocumab to become gold standard among add-on statin therapies

Amgen’s evolocumab to become gold standard among add-on statin therapies

22-07-2014

Leading independent biotech firm Amgen’s investigational compound evolocumab (AMG-145) is set to become…

AmgenBiotechnologyCardio-vascularCardiovascular diseaseEuropeevolocumabMarkets & MarketingUSA

BIND Thera and Amgen end their Accurin collaboration

BIND Thera and Amgen end their Accurin collaboration

03-07-2014

US clinical stage drug developer BIND Therapeutics saw its shares plunge 15.8% to $10.84 in after-hours…

AccurinsAmgenBIND TherapeuticsBiotechnologyLicensingOncology

Breakthrough status for Amgen’s blinatumomab in ALL

01-07-2014

USA-based Amgen, the world's largest independent biotech firm, says that the US Food and Drug Administration…

AmgenBiotechnologyblinatumomabOncologyRegulationUSA

Teva ready to pay up to $825 million for Labrys Biologics, and its novel migraine treatment

Teva ready to pay up to $825 million for Labrys Biologics, and its novel migraine treatment

03-06-2014

Israel generics giant Teva Pharmaceutical Industries has entered into a definitive agreement to acquire…

AmgenBiotechnologyLabrys BiologicsLBR-101Mergers & AcquisitionsNeurologicalTeva Pharmaceutical Industries

Amgen’s Vectibix approved for colorectal cancer by FDA

Amgen’s Vectibix approved for colorectal cancer by FDA

27-05-2014

USA-based Amgen, the world's leading independent biotech firm, has announced that the US Food and Drug…

AmgenBiotechnologyChemotherapy regimensMetastatic colorectal cancerOncologyRegulationUSAVectibix

Amgen names Steven Galson, Senior Vice President, Global Regulatory Affairs and Safety

Amgen names Steven Galson, Senior Vice President, Global Regulatory Affairs and Safety

14-05-2014

US biotech firm Amgen has announced the appointment of Steven Galson to the position of senior vice president,…

AmgenBiotechnologyBoardroomUSA

Evolocumab combined with statin results in further reduction of cholesterol levels

Evolocumab combined with statin results in further reduction of cholesterol levels

14-05-2014

Among patients with high cholesterol receiving moderate- or high-intensity statin therapy, the addition…

AmgenBiotechnologyCardio-vascularevolocumabResearch

Amgen and AstraZeneca’s brodalumab meets all endpoints in Ph III study

Amgen and AstraZeneca’s brodalumab meets all endpoints in Ph III study

10-05-2014

Anglo-Swedish drug major AstraZeneca and the USA’s Amgen have announced that the Phase III AMAGINE-1…

AmgenAstraZenecaBiotechnologybrodalumabInflammatory diseasesResearch

Oxford BioTherapeutics uses Amgen’s Xenomouse antibodies for breast cancer

07-05-2014

UK biotech company Oxford BioTherapeutics has obtained the exclusive global rights to USA-based Amgen’s…

AmgenBiotechnologyImmunoGenLicensingOncologyOxford BioTherapeutics

Amgen's 1st-qtr 2014 disappoints, as net income falls 25%

23-04-2014

Amgen, the world’s largest independent biotech firm by revenues, yesterday announced financial results…

AmgenBiotechnologyFinancialResearch

Disappointing results with Amgen’s talimogene laherparepvec in metastatic melanoma

Disappointing results with Amgen’s talimogene laherparepvec in metastatic melanoma

06-04-2014

Leading independent biotech firm Amgen has released mixed top-line results from the primary overall survival…

AmgenBiotechnologyOncologyResearchtalimogene laherparepvec

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

04-04-2014

World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlineLicensingProliaXgeva

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

31-03-2014

USA-based Amgen announced data at the American College of Cardiology 63rd Annual Scientific Session this…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

More positive Ph III data for Amgen’s evolocumab

More positive Ph III data for Amgen’s evolocumab

17-03-2014

Leading independent biotech firm Amgen has released more positive clinical trial data with its cholesterol…

AmgenBiotechnologyCardio-vascularevolocumabRare diseasesResearch

Retrospective analysis shows tumor shrinkage with Amgen's talimogene laherparepvec

Retrospective analysis shows tumor shrinkage with Amgen's talimogene laherparepvec

16-03-2014

Leading independent biotech firm Amgen says that findings from a pre-specified retrospective analysis…

AmgenBiotechnologyOncologyResearchtalimogene laherparepvec

Genentech regains its dominance in image among oncologists

Genentech regains its dominance in image among oncologists

20-02-2014

Genentech, the biotechnology subsidiary of Swiss drug major Roche, has made notable gains as the top…

AmgenBiotechnologyCelgeneGenentechHematologyMarkets & MarketingNovartisOncologyResearch

Advanced melanoma collaboration for Amgen and Merck & Co

Advanced melanoma collaboration for Amgen and Merck & Co

05-02-2014

World leading independent biotech firm Amgen and US pharma giant Merck & Co have entered into an agreement…

AmgenBiotechnologyMerck & CoMK-3475OncologyResearchtalimogene laherparepvec

Systemic psoriasis market forecast to reach $10.4 billion by 2020

05-02-2014

The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

Amgen announces top-line results from Phase III trial of evolocumab

Amgen announces top-line results from Phase III trial of evolocumab

29-01-2014

USA-based Amgen announced that the Phase III LAPLACE-2 trial evaluating evolocumab (AMG 145) in combination…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

Amgen again tops analysts’ forecasts as profits rise 30%

Amgen again tops analysts’ forecasts as profits rise 30%

29-01-2014

Amgen, the world’s largest independent biotech firm, for the fifth reporting quarter beat analysts’…

AmgenBiotechnologyFinancial

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

24-01-2014

USA-based Amgen yesterday revealed positive results from the Phase III GAUSS-2 (Goal Achievement After…

AmgenBiotechnologyCardio-vascularevolocumabResearchZetia

Amgen and Illumina to develop companion diagnostic for Vectibix

Amgen and Illumina to develop companion diagnostic for Vectibix

16-01-2014

USA-based Illumina has entered into an agreement with Amgen to develop and commercialize a multigene,…

AmgenBiotechnologyIlluminaOncologyResearchVectibix

Amgen launches collaboration with academia for IBD drug development

15-01-2014

US biotech firm Amgen says it has launched a strategic collaboration with Massachusetts General Hospital…

AmgenBiotechnologyGastro-intestinalsMarkets & MarketingResearch

1 to 25 of 115 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top